Skip to Content
Merck
CN

SML3026

BAY-786

≥98% (HPLC)

Synonym(s):

(2R)-N-[[3-Chloro-5-(trifluoromethyl)-2-pyridyl]methyl]-2-cyclopropyl-1-(4-fluorophenyl)sulfonyl-1′,1′-dioxo-spiro[indoline-3,4′-thiane]-5-carboxamide, (2R)-N-[[3-chloro-5-(trifluoromethyl)-2-pyridinyl]methyl]-2-cyclopropyl-1-[(4-fluorophenyl)sulfonyl]-1,2,2,3,5,6-hexahydro-spiro[3H-indole-3,4-[4H]thiopyran]-5-carboxamide 1,1-dioxide

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Empirical Formula (Hill Notation):
C29H26ClF4N3O5S2
CAS Number:
1631164-25-4
Molecular Weight:
672.11
UNSPSC Code:
12352200
NACRES:
NA.77

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

BAY-786, ≥98% (HPLC)

InChI key

PZGSYNNVPNLHQG-AREMUKBSSA-N

SMILES string

O=C(C1=CC2=C(N(S(=O)(C3=CC=C(F)C=C3)=O)[C@H](C4CC4)C2(CC5)CCS5(=O)=O)C=C1)NCC6=NC=C(C(F)(F)F)C=C6Cl

assay

≥98% (HPLC)

form

powder

optical activity

[α]/D 105 to 125°, c = 0.5 in chloroform-d

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

2-8°C

Quality Level

100

Biochem/physiol Actions

BAY-786 is a negative control for an orally available, non-toxic, potent, and selective GnRH-R antagonist BAY-784.
negative control for an orally available, non-toxic, potent, and selective GnRH-R antagonist BAY-784

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000127874
0000127873
0000125585

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Olaf Panknin et al.
Journal of medicinal chemistry, 63(20), 11854-11881 (2020-09-23)
The growth of uterine fibroids is sex hormone-dependent and commonly associated with highly incapacitating symptoms. Most treatment options consist of the control of these hormonal effects, ultimately blocking proliferative estrogen signaling (i.e., oral contraceptives/antagonization of human gonadotropin-releasing hormone receptor [hGnRH-R]

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service